Part 1: Why test?
Prof Nickolas Papadopoulos speaks to ecancer about a first-of-its-kind prospective study of a multi-cancer blood test to screen and manage 10,000 women with no history of cancer.
He explains that the study was carried out prospectively in order to mimic real world situations and be able to test individuals who had no suspicion of cancer.
Prof Papadopoulos describes how a PET-CT would be carried out if there was a suspicion of cancer in order to validate and localise a lesion.
He believes that the blood test can be integrated in to the standard of care screening rather than replacing it.
Part 1: Why test?
Part 2: How to get biopsies for testing?
SABCS 2025: Latest developments in multigene testing in early breast cancer
AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
Cancer mutation prediction using artificial intelligence
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Best practice in HRRm testing in patients with metastatic prostate cancer
Looking at real world evidence on PSA testing in prostate cancer